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Summary
Starting from the X-ray structure of a class I major histocompatibility complex (MHC)-encoded protein
(HLA-B*2705), a naturally presented self-nonapeptide and two synthetic analogues were simulated in
the binding groove of two human leukocyte antigen (HLA) alleles (B*2703 and B*2705) differing in a
single amino acid residue. After 200 ps molecular dynamics simulations of the solvated HLA–peptide
pairs, some molecular properties of the complexes (distances between ligand and protein center of
masses, atomic fluctuations, buried versus accessible surface areas, hydrogen-bond frequencies) allow
a clear discrimination of potent from weak MHC binders. The binding specificity of the three nonapep-
tides for the two HLA alleles could be explained by the disruption of one hydrogen-bonding network
in the binding pocket of the HLA-B*2705 protein where the single mutation occurs. Rearrangements
of interactions in the B pocket, which binds the side chain of peptidic residue 2, and a weakening of
interactions involving the C-terminal end of the peptide also took place. In addition, extension of the
peptide backbone using a β-Ala analogue did not abolish binding to any of the two HLA-B27 subtypes,
but increased the selectivity for B*2703, as expected from the larger peptide binding groove in this
subtype. A better understanding of the atomic details involved in peptide selection by closely related
HLA alleles is of crucial importance for unraveling the molecular features linking particular HLA alleles
to autoimmune diseases, and for the identification of antigenic peptides triggering such pathologies.
Introduction
Major histocompatibility complex (MHC)-encoded
class I proteins play a major role in the immune surveil-
lance of intracellular pathogens by presenting antigenic
peptides to cytotoxic T-lymphocytes (CTLs) at the surface
of infected cells [1]. In the last decade, tremendous re-
search efforts have been made to delineate the molecular
aspects of antigen presentation to CTLs. Three major
breakthroughs in this field were the description of the
first class I MHC crystal structure [2], the identification
of allele-specific motifs for naturally bound peptides [3],
and the prominent role played by MHC-encoded TAP
heterodimers for antigen transport [4]. Starting from these
three major observations, experimental data on antigen
presentation to MHC proteins are presently accumulating
at an incredible pace. The huge amount of molecular
details have made human leukocyte antigen (HLA) pro-
teins very interesting drug design targets for two reasons.
First, it is likely that the three-dimensional (3D) structures
of all class I and class II alleles are very similar, and that
the MHC binding mode is rather conserved for most of the
presented peptides, within each HLA class [5,6]. Reliable
3D pictures of MHC–peptide complexes are now accessible
and can be interpreted with respect to biological data [7–
10]. Second, the expression of certain MHC alleles is asso-
ciated with either resistance or susceptibility to human
immunological diseases like ankylosing spondylitis [11],
diabetes [12], rheumatoid arthritis [13] or malaria [14].
One of the strongest linkages known to date between
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the expression of one class I HLA allele and susceptibility
to a pathology is that of HLA-B27 to inflammatory dis-
eases of the joints called spondyloarthropathies [15,16].
For example, more than 95% of patients suffering from
ankylosing spondylitis are HLA-B27 positive, while this
MHC type is only expressed in 7% of the healthy popula-
tion [11]. Interestingly, among the 11 HLA-B27 alleles
(HLA-B*2701 to HLA-B*2711) reported to date, at least
two are not associated with spondyloarthropathies: HLA-
B*2706 [17,18] and HLA-B*2709 [19]. All subtypes differ
among each other only at a few residues, mostly located
in the peptide binding groove.
Deciphering the molecular parameters responsible for
the binding of antigenic peptides to the different HLA-
B27 subtypes is an absolute prerequisite for better under-
standing their differential association with susceptibility
to spondyloarthropathy, and to identify the sequence of
potential arthritogenic peptides [15] that may trigger the
disease. Sequencing of peptides naturally presented by the
different alleles [20–26] shows that Arg at position 2 (P2)
is a conserved motif for peptides binding to all subtypes.
Gln2 is an additional motif among B*2701-bound pep-
tides [25], but is a suboptimal residue (not found in vivo)
for other subtypes [27–30]. Two other anchoring positions
could be disclosed from the frequency of occurrence of
amino acids in peptides naturally bound to B*2705. Hy-
drophobic amino acids are preferred at P3, and hydro-
phobic as well as positively charged residues can be found
at P9. Other positions are more variable and probably
indicate a less important binding role. These observations
are compatible with the crystal structure of one allele
(HLA-B*2705) in complex with a peptide pool [31,32]. As
for all other class I alleles crystallized to date, bound
ligands are mainly nonapeptides strongly hydrogen-
bonded in a sequence-independent manner at their N-
and C-termini to both ends of the MHC binding groove.
The central part of the peptide (from P4 to P8) bulges out
of the binding groove (Fig. 1) [32]. Some peptide side
chains (P2, P3 and P9) are responsible for the allele speci-
ficity of the recognition process, by binding to comple-
mentary pockets of the MHC. Notably, the conserved
Arg2 of B27-bound peptides is perfectly centered in a
polar subsite (pocket B) composed of MHC polymorphic
residues (Tyr7, His9, Thr24, Glu45, Cys67). HLA-B*2705 is
the only B27 subtype that has been crystallized up to
now. Furthermore, although peptide binding motifs have
been described for various HLA-B27 subtypes, the exact
peptide repertoire selected by each allele is still under
investigation, and the exact contribution of individual
amino acids at the nine peptide positions to the various
subtypes remains largely unknown.
HLA-B*2703 contains a single point mutation
(Tyr59→His) in a subsite (pocket A) responsible for the
binding of the peptide N-terminal residue. HLA-B*2703
probably selects a subset of peptides presented by the
common HLA-B*2705 allele [33,34]. Positively charged
residues (Lys, Arg and His) at P1 have been proposed to
be one of the main characteristics of this subset common
to both subtypes as the replacement of Ser1 by Arg re-
stored the binding of a B*2705-restricted viral epitope to
HLA-B*2703 [35]. In addition, basic residues were pre-
dominant among self-peptides naturally bound to B*2703
[23]. Additional interactions given by basic side chains
could compensate for the weaker interaction of the pep-
tide N-terminus to B*2703 pocket A. However, this is not
a stringent requirement because amino acids other than
Arg/Lys at P1 (Ala for example) are compatible with a
good binding to this allele [28].
To rationalize these data, molecular dynamics (MD)
simulations of both alleles in complex with three different
peptides were undertaken to delineate similarities and dif-
ferences in MHC binding, which may explain specificity
variations.
Materials and Methods
Coordinates setup
Starting coordinates were taken from the crystal struc-
ture of HLA-B*2705, solved at 2.1 Å resolution [32] and
deposited in the Brookhaven Protein Databank [36] with
the entry 1HSA. In order to save computational time,
only the antigen-binding α1–α2 domains were taken into
account in the study. This approximation was previously
shown not to alter the accuracy of MD simulations
[9,37,38] because only limited interactions exist between
the α1-α2 part and the other two domains (α3 and β2m)
that do not significantly contact antigenic peptides in the
binding groove. This observation has been validated by
the crystal structure of one class I MHC protein lacking
the membrane-proximal α3 domain, for which a con-
served 3D fold of the α1–α2 antigen-binding domain was
reported [39]. The C-terminal residue of the α2 domain
(Thr182) was protected by an N-methyl group to avoid
unrealistic electrostatic interactions. The HLA-B*2703
subtype was obtained from the HLA-B*2705 crystal
structure by mutating Tyr59 into His, without changing
the direction of the side chain. All MHC-bound nonamers
were built from the peptide (ARAAAAAAA) modeled in
the original crystal structure [32] by substituting the cor-
responding residue for alanine without altering the direc-
tion of the side chains. Six crystal water molecules were
explicitly taken into account, as they are located in the
peptide binding cleft and bridge the binding of the pep-
tide to the protein X-ray structure. Polar hydrogen atoms
were then added and the complexes were centered in a 7.5
Å thick shell of TIP3P water molecules [40] without posi-
tional constraint on solvent atoms. Any water atom closer
than 1.75 Å to any solute atom was discarded, so that
approximately 1500 water molecules were added to each
MHC–peptide binary complex.
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Parametrization of the N-terminal b-alanine monomer
The N-terminal β-alanine was parametrized for
AMBER 4.0 [41] using a previously described procedure
[42]. Briefly, atomic coordinates for β-alanine were ob-
tained from the SYBYL biopolymer dictionary [43] and
optimized by semiempirical quantum mechanics (MOPAC
6.0) using the PM3 Hamiltonian [44]. Potential-derived
atomic charges were then computed on this geometry by
a single-point SCF calculation at the MNDO level [45].
As new atom types were not defined, nonexisting force
constants have been assigned according to available
AMBER values for closely related bond, angle and di-
hedral types. They were incorporated into the parm91
parameter set.
Molecular mechanics and dynamics simulations
All computations were performed on a CRAY J90
using the AMBER 4.0 program [41] and the united-atom
representation of the parm91 parameter set. Since explicit
water molecules were taken into account, a dielectric
constant of 1 was used for all calculations. To avoid
splitting dipoles, nonbonded interactions were calculated
within a residue-based cutoff of 10 Å. The solvent atoms
were first relaxed by 1000 steps of steepest descent energy
minimization, the solute being held fixed. The solvated
complex was then fully minimized by 1000 steps of steep-
est descent, followed by a conjugate gradient minimiza-
tion procedure until the rms gradient of the potential
energy was less than 0.25 kcal mol−1 Å−1. The minimized
coordinates were thereafter used as a starting point for an
MD simulation at constant temperature. Initial velocities
were taken from a Maxwellian distribution at 50 K and
an integration step of 2 fs was used. The system was
progressively heated from 50 to 297 K during the first
picosecond, the temperature being held at 297 K for the
rest of the simulation by coupling the system to a heat
bath [46] using a temperature coupling constant of 0.05
ps. All bond lengths were constrained to their equilibrium
values using the SHAKE algorithm [47] with a bond
length tolerance of 2.5 × 10−4 Å. Coordinates, energies and
velocities were collected and saved every 250 steps (0.5 ps)
for 200 ps. The analyses of MD trajectories were achieved
using in-house routines and the CARNAL module of
AMBER [41].
Calculation of electrostatic interaction energies
Electrostatic free energies were computed by solving
the linear form of the Poisson–Boltzmann equation using
the finite-difference method [48,49] of the DelPhi program
[50,51]. Peptides, MHC proteins and MHC–peptide com-
plexes were centered in three-dimensional boxes with
resolutions of 2.0, 1.20 and 1.10 grid points per Å, re-
spectively. For each calculation, 90% of the box was filled
with the corresponding molecule. Atomic radii and
charges were taken from the AMBER 4.0 united-atom
parameter set [41]. Inner and outer dielectrics were as-
signed values of 2.0 and 1.0 (vacuum) or 80 (water envi-
ronment). An ionic strength of 0.145 M and an ion exclu-
sion radius (Stern layer) of 2.0 Å were used according to
previously reported solvent calculations [51]. A probe
radius of 1.8 Å was utilized for computing the surface at
which the electrostatic potential was extrapolated.
Peptide synthesis
Peptides 1 and 3 were synthesized as previously de-
scribed [28]. Peptides 2 and 4 were synthesized by auto-
mated, multiple solid-phase peptide synthesis with a robot
system (Syro, MultiSynTech, Bochum, Germany) using
an Fmoc/tBu strategy. For side-chain protection, Tyr(tert-
butyl), Ser(tert-butyl), Thr(tert-butyl), Glu(tert-butyl),
Gln(trityl), Arg(2,2,3,5,5-pentamethyl-chromansulfonyl)
and Lys(tert-butyloxy-carbonyl) were used. The N-ter-
minal residues were obtained using single couplings with
diisopropylcarbodiimide/1-hydroxy-benzotriazole activa-
tion, 10-fold excess and a coupling time of 1 h on the 2-
chlorotritylchloride resin. The peptides were cleaved with
trifluoroacetic acid/thioanisole/thiocresol (20:1:1) within
3 h, collected by centrifugation and lyophilized from
water.
They were then purified by reversed-phase HPLC
(Merck-Hitachi, Darmstadt, Germany) on a nucleosil 5
µM/C18 column (125 × 3 mm) at a flow rate of 600 µl/min.
The absorbance was measured at 220 nm. The solvent
system used consisted of 0.1% trifluoroacetic acid in
water (A) and 0.1% trifluoroacetic acid in acetonitrile (B).
A linear gradient from 10 to 60% B in 30 min was ap-
plied. The peptides were purified to homogeneity by a
second HPLC on a versapack 10 µm C18 column (300 ×
7.8 mm) at a flow rate of 2 ml/min with the same buffer
system, and a linear gradient from 0 to 40% B in 35 min
followed by a 40–60% B linear gradient for 20 min. Fur-
thermore, the peptides were analyzed by ion spray mass
spectrometry on a triple-quadrupole mass spectrometer
API III with a mass range of m/z = 10–2400 equipped
with an ion spray interface (Sciex, Thornhill, ON,
Canada), and quantified by amino acid analysis using a
6300 amino acid analyser (Beckman, Palo Alto, CA,
U.S.A.).
Peptide binding assay
The quantitative assay used has been described previ-
ously [29]. Briefly, RMA-S transfectants expressing
B*2705 or B*2703 were used. These are murine cells with
impaired TAP-mediated peptide transport and low sur-
face expression of (empty) class I MHC molecules, which
can be induced at 26 °C [52] and stabilized at the cell
surface through the binding of exogenously added pep-
tides. These cells were incubated at 26 °C for 24 h. After
this, they were incubated for 1 h at 26 °C with 10−4–10−9
M peptides, transferred to 37 °C and collected for flow
466
microcytometry (FMC) analysis with the ME1 mAb
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Fig. 1. Orientation of a canonical nonapeptide (ball-and-stick model) in the binding groove of HLA-B27 (cyan ribbons) [32]. Peptide positions
are labeled at the Cα atoms from 1 (P1) to 9 (P9). MHC specificity pockets (A to F) are displayed according to the usual nomenclature [72]. The
figure has been obtained with the MOLSCRIPT [73] and Raster3D [74] programs.
TABLE 1
RELATIVE BINDING OF THREE NONAPEPTIDES TO TWO
HLA-B27 SUBTYPES
Peptide Sequence Relative bindinga
B*2703 B*2705
1 RRYQKSTELb 1 (2×10−6) 1 (2×10−6)
2 ARYQKSTEL 1.5 2
3 RQYQKSTEL >>100 10
a Data are expressed as the molar excess of peptide analogue, relative
to the wild-type peptide 1, at which HLA-B27 fluorescence (meas-
ured by FMC analysis with an anti-B27 monoclonal antibody) on
RMA-S cells was half the maximum obtained with peptide 1. The
molar concentration of peptide 1 at 50% maximum fluorescence
(C50) is given in parentheses.
b Human histone H3 peptide: a self-peptide, naturally bound to HLA-
B*2705 [20] and to B*2703 [23]. Dominant anchor residues are dis-
played in boldface.
(IgG1, specific for HLA-B27, B7 and B22) [53] after 4 h
for B*2705, or after 2 h for B*2703. The determinant
recognized by ME1 is not affected by bound peptides or
by HLA-B27 polymorphism (data not shown). The bind-
ing of a given peptide was measured as its C50. This is its
molar concentration at 50% of the fluorescence obtained
with that peptide at 10−4 M. Peptides with C50 ≤ 5 µM
were considered to bind with high affinity, as these were
the values obtained for most of the natural B27-bound
ligands. C50 values between 5 and 50 µM were considered
to reflect intermediate affinity. C50 ≥ 50 µM indicated low
affinity. Peptides having C50>100 µM were assumed not
to bind. The binding of peptide analogues was measured
as the concentration of the peptide analogue required to
obtain the fluorescence value at the C50 of the unchanged
peptide. This was designated as EC50. Relative binding
was expressed as the ratio between the EC50 of the pep-
tide analogue and the C50 of the corresponding unchanged
peptide.
Results and Discussion
A naturally bound nonapeptide (1) from the human
histone H3 protein was taken as reference for its equal
binding to both subtypes (Table 1). The Ala1 analogue (2)
was chosen for its unexpected high affinity for both sub-
types [28,35]. Finally, the Gln2 analogue 3 of the human
histone peptide was also studied, in order to investigate
the influence of pocket B–P2 interactions that may also
participate in the peptide discrimination [28].
Dynamical properties of MHC–peptide complexes
Monitoring instantaneous rms deviations (rmsd’s) of
protein atoms from the starting structure is usually per-
formed to ascertain the reliability of MD simulations [54].
For both alleles complexed to peptides 1–3, similar rmsd
values were observed (about 1.7 Å for backbone atoms;
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data not shown), indicating that protein distortion upon
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Fig. 2. Time course of the distance (in Å) between the center of mass of peptides 1–3 and that of the host HLA-B27 subtype (a: B*2703; b:
B*2705).
ligand binding cannot account for the different binding
affinities of these peptides. Stable rmsd values (1–1.5 Å)
were also observed for bound peptides. Interestingly, they
remain in the same range as that observed for different
peptides co-crystallized with the same MHC host protein
[55,56]. One exception concerns the weakest binder (pep-
tide 3 to HLA-B*2703), for which larger distortions (up
to 2.5 Å) were observed and still increasing after 200 ps
simulation.
To follow a possible dissociation of peptides 1–3 from
the two HLA-B27 alleles, the distance between ligand and
protein center of mass (cmass) was monitored. For bind-
ing peptides (1, 2), whatever the B27 subtype, this inter-
molecular distance increases during the warm-up phase
from 8 to 8.5 Å and remains constant for the rest of the
simulation (Fig. 2). The weak binder (peptide 3) exhibits
a slight but continuous increase of the intermolecular
distance, suggesting a partial dissociation of the ligand
from the binding groove. This phenomenon was signifi-
cantly enhanced for the less stable complex (3a: peptide
3 in complex with HLA-B*2703). However, localization
of the dissociating peptide amino acids is not possible
with this analysis. For example, TcR-binding residues
may bulge even more out of the peptide binding site and
induce similar shifts in the intermolecular distance be-
tween center of masses.
Therefore, this analysis was extended by computing the
cmass of bound peptide substructures (MHC anchors: P1,
P2, P3, P9; TcR anchors: P4, P5, P6, P7, P8) for each
MD conformation and the distance relating it to the
protein cmass (Table 2). An examination of d2 and d3
intermolecular distances for the weak binder 3 clearly
shows that MHC-anchoring amino acids only are pro-
gressively expelled from the binding groove. The dissocia-
tion is more significant when compound 3 is complexed
to HLA-B*2703, which relates well with the observed
binding data (Table 1). The TcR-binding region (P4–P8)
is similarly bulging out (at least quantitatively) of the
binding cleft for all the six studied complexes (d3 dis-
tance, Table 2). An even more precise analysis has been
done by evaluating the inter-cmass distance between
individual MHC anchor residues and their complemen-
tary pocket (A, B, D and F; d4–d7 distances, Table 2).
Surprisingly, the repulsion noticed for peptide 3 in com-
plex with both alleles seems to be located at the
P9–pocket F interaction level (d7 = 7.3 Å), far from where
protein and peptide single-point mutations occur. Interest-
ingly, the critical d5 distance, illustrating the strength of
the most important interaction between the invariant Arg2
and pocket B, is higher (5.1 ± 0.4 Å) for the less stable
complex (3a) than for other pairs (Table 2). The different
d4 distances reported here, especially for peptides 1 and
3 and peptide 2, are related to the size of the correspon-
ding P1 side chain (Arg versus Ala). It indicates that the
Arg1 side chain is pointing away from its binding subsite
(pocket A) and therefore induces higher d4 inter-cmass
distances. However, for a given P1 side chain, higher d4
distances are always observed for HLA-B*2703. This
indicates that the Tyr59→His mutation found in the latter
allele is detrimental for a stable and strong binding of P1
side chains to pocket A of the protein. The highest stan-
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dard deviations are found for the P3–pocket D interac-
TABLE 2
DISTANCE BETWEEN PROTEIN AND PEPTIDE CENTER OF MASSES
Distance (Å) Peptide
1a 1b 2a 2b 3a 3b
d1 08.2 ± 0.3 08.5 ± 0.3 08.3 ± 0.3 08.2 ± 0.4 09.3 ± 0.9 09.1 ± 0.7
d2 05.9 ± 0.3 05.9 ± 0.3 05.5 ± 0.3 05.6 ± 0.4 07.3 ± 0.5 06.6 ± 0.5
d3 11.5 ± 0.4 12.1 ± 0.5 12.3 ± 0.5 10.7 ± 0.5 12.0 ± 0.6 12.3 ± 0.6
d4 03.6 ± 0.3 02.9 ± 0.4 02.3 ± 0.3 01.5 ± 0.5 03.4 ± 0.4 02.8 ± 0.3
d5 04.7 ± 0.2 04.7 ± 0.3 04.7 ± 0.3 04.4 ± 0.3 05.1 ± 0.4 04.7 ± 0.3
d6 04.9 ± 0.6 04.8 ± 0.5 05.3 ± 0.5 05.0 ± 0.7 04.6 ± 0.5 05.2 ± 0.6
d7 02.5 ± 0.4 02.6 ± 0.3 02.9 ± 0.3 03.4 ± 0.4 07.3 ± 0.6 04.8 ± 0.5
d1: protein–peptide; d2: protein–MHC anchors (P1–P3, P9); d3: protein–TcR anchors (P4–P8); d4: pocket A–P1; d5: pocket B–P2; d6: pocket
D–P3; d7: pocket F–P9.
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Fig. 3. Rms atomic fluctuations of peptides 1–3 when bound to an HLA-B27 protein (a: B*2703; b: B*2705). Pn represents the peptide position
(from 1 to 9).
tion (d6, Table 2). The 0.6 Å variations, observed in such
nonbonded distances, correspond to the alternative estab-
lishment of strong and weak hydrophobic contacts, which
may be explained by the topology of the binding groove.
Pocket D is a hydrophobic subsite open to the central
part of the binding cleft, and partially filled by hydro-
phobic side chains [20]. The significantly higher variance
of the d6 distance (Table 2) suggests that this interaction
is the most flexible one and that different local conforma-
tions at P3 are compatible with a good occupancy of
pocket D. Retrospectively, it explains why the P3–pocket
D interaction may be important for an optimal peptide
binding to HLA-B*2705. Bulky hydrophobic nonnatural
side chains (α- and β-naphthylalanine, cyclohexylalanine)
have been shown to significantly enhance binding to the
HLA-B*2705 protein [38,57]. This positive effect probably
results from two correlated components: (i) the existence
of additional contacts to pocket D, a pure enthalpic ef-
fect; and (ii) a reduced flexibility of the MHC-bound P3
side chain, a favorable entropic effect.
Atomic fluctuations
Atomic fluctuations of MHC-bound peptides were com-
puted from mean conformations, time-averaged over the
last 50 ps (Fig. 3). As expected, MHC anchors are much
less flexible than the TcR-binding middle part. If atomic
mobility of the bound ligand is considered, it is not poss-
ible to depict real differences in the binding of peptides 1
and 2 to the two subtypes. However, the C-terminal an-
chor residue clearly tends to be more flexible when the
corresponding ligand does not strongly bind to the B27
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subtype. The highest flexibilities are observed for the
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Fig. 4. Ratio of accessible to buried surface area for relaxed MD time-averaged conformations. Surface areas were calculated with the MS program
[75] using a 1.4 Å probe radius. High ratios were truncated to a value of 2.0. Pn represents the peptide position (from 1 to 9).
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Fig. 5. MHC–peptide H-bonding frequency for peptides 1–3 in complex with HLA-B27 subtype (a:B*2703; b: B*2705). H-bonds have been
geometrically defined by an acceptor (A) to donor (D) distance less than 3.25 Å and a D-H..A angle greater than 120°. Interactions were
statistically monitored throughout the simulations for a total of 400 conformations per MHC–peptide complex. Two categories of H-bonds were
defined: strong ones with frequencies higher than 50% and medium ones with occurrences between 25 and 50%.
weakest binder (peptide 3 to B*2703), especially at the
important anchoring positions (P2, P3 and P9). It is logi-
cal to find that the mutation at P2 (for peptide 3)
weakens the interactions to MHC pocket B that has been
designed to accommodate an arginine side chain [32].
However, the P2 amino acid is more flexible when the
corresponding peptide is complexed to HLA-B*2703
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(compare 3a and 3b, Fig. 3). Again, the most striking
Tyr59  His59
Glu45
Glu63
Tyr171
Trp167
Met5 Tyr159
Tyr99
His9
Thr24
Tyr7
P1
P2
Fig. 6. Crystal structure of HLA-B*2705 [32]. The view is focused on MHC pocket A (Met5, Tyr7, Tyr59, Glu63, Tyr159, Trp167, Tyr171) and pocket
B (His9, Thr24, Glu45, Tyr99) side chains interacting via H-bonds (direct H-bonds: green broken lines; water-mediated H-bonds: yellow broken lines)
with the P1–P2 positions of a bound peptide. The following color coding has been used: carbon, white (protein) or orange (peptide); nitrogen,
blue; oxygen, red; sulfur, yellow. Bound water molecules are shown as cyan balls. Arrows indicate the direction of the H-bonds (from the donor
to the acceptor). HLA-B*2703 was obtained by mutating Tyr59 into His (SYBYL Biopolymer module) [43]. The side-chain χ2 dihedral was just
modified here in order to bring the Nε atom as close as possible to the bound water molecule. However, whatever the rotamer chosen, a direct
H-bond to a water molecule is not possible. The interatomic distance between the peptide N-terminus and Tyr59 (OH) or His59 (Nε2) atoms is 4.31
and 5.35 Å, respectively. Figures 6–8 have been obtained by using the rendering program Raster 3D [74].
differences are not observed at the variable amino acids
of the peptides (P1, P2) but at the C-terminal anchor
(P9), a feature already noticed for other MHC–peptide
complexes [9]. One may hypothesize that the N-terminal
tripeptide (P1-P2-P3) determines the stability of peptide–
MHC interactions over the whole length of the binding
groove by controlling the conformational space accessible
to the bulging middle part and, consequently, the binding
capacity of the following C-terminus. However, atomic
flexibilities of the P1–P3 and P4–P8 parts are not interre-
lated. It is also possible that these differences are related
to the short time scales (200 ps) used for simulating the
complexes and that much longer simulations are needed
to see significant molecular differences at positions P1
and P2 of the peptide ligand. Nanosecond MD simula-
tions of macromolecules are nowadays feasible [58,59],
but still remain unrealistic as a structure–activity relation-
ship tool for comparing a series of ligands in their pro-
tein-bound state.
Accessible versus buried surface areas
Whether peptide flexibility correlates with dissociation
from the binding cleft was addressed by looking at access-
ible and buried surface areas of each HLA-bound peptide
residue (Fig. 4). Only position 9 of peptide 3 in complex
with B*2703 was much more accessible than the others.
Otherwise, the main anchor P2 was similarly buried what-
ever the peptide and the host HLA protein. This means
that a partial dissociation was only observed for one
position (P9) in one complex (3a) and that the previously
reported higher flexibility of Gln2 for the same peptide–
MHC complex did not correspond with a release of the
P2 side chain from pocket B. It may however influence
the quality and frequency of hydrogen bonds between the
Gln2 side chain and pocket B of both B27 alleles. The
influence of secondary anchor positions is more difficult
to ascertain. P3 is similarly buried for all MHC–peptide
complexes. P6 (Ser) and P7 (Thr) positions are probably
accessory anchor positions that marginally bind, in some
conformations, to the central part of the peptide binding
groove (pockets C/E). This observation is not incompat-
ible with the high atomic fluctuations of P6-P7 amino
acids (Fig. 3), as their side chains are directed towards the
binding groove but without reaching its floor. P4 (Gln),
P5 (Lys) and P8 (Glu) residues are potential candidates
for TcR recognition because of their concomitant atomic
flexibility and surface accessibility.
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Qualitative and quantitative analysis of peptide–MHC H-
Glu45Glu63
Tyr171
Trp167
Met5
Tyr159
Tyr99
His9
Thr24
Tyr7
P1
P2
His59
Fig. 7. MD model of complex 3a, focused on MHC pockets A–B (see the legend to Fig. 6). A mean conformation was averaged from the last 100
conformers and submitted to 500 steps of steepest descent, followed by 1500 steps of conjugate-gradient energy relaxation.
Glu45
Glu63
Tyr171 Trp167
Met5 Tyr159
Tyr99
His9
Thr24
Tyr7
P1
P2
Tyr59
Glu163
Fig. 8. MD model of complex 3b, focused on MHC pockets A–B (see the legend to Fig. 6). The mean conformation was obtained as described
in Fig. 7.
bonds
Reporting the number of MHC–peptide H-bonds as
well as their frequencies during the simulation allows a
clear distinction between peptides 1 and 2 and the Gln2
analogue (peptide 3, Fig. 5). The stability of protein–
peptide H-bonds was assessed by computing the frequency
of occurrence of the interaction throughout the MD tra-
472
jectory (400 conformations). A frequency higher than 50%
TABLE 3
MHC–PEPTIDE H-BONDS WITH A FREQUENCY HIGHER
THAN 50%
Pn atom HLA-B27 1a 1b 2a 2b 3a 3b
P1 N Tyr7 (OH) 1 1 1
His59 (NE2) 1 1 1
Glu45 (OE2) 3
Glu63 (OE1) 1 1 1
Glu63 (OE2) 1 1
Glu163 (OE2) 3
NE Glu163 (OE2) 1 × × 1
NH2 Glu63 (OE1) × × 3
Glu63 (OE2) × × 3
O Tyr159 (OH) 1 1 1 1
P2 N Glu63 (OE1) 1 1
Glu63 (OE2) 1 1
NE Glu45 (OE2) 3 × ×
Glu63 (OE1) 3 × ×
OE1 Tyr99 (OH) × × × × 3
NE2 His9 (NE2) × × × × 3
Glu45 (OE2) × × × × 3
NH1 His9 (NE2) 1 1 1 × ×
Thr24 (OG1) 3 × ×
NH2 Thr24 (OG1) 1 1 1 × ×
Glu45 (OE1) 1 1 1 × ×
Glu45 (OE2) 1 1 1 × ×
Glu63 (OE1) 3 × ×
P3 N Tyr99 (OH) 1 1 1 1
P6 OG Ala69 (O) 1
Thr73 (OG1) 1
P8 O Trp147 (NE1) 1 1 1
OE1 Lys146 (OE1) 1
P9 N Asp77 (OD1) 1 1 1 1 1
OXT Tyr84 (OH) 1
Thr143 (OG1) 1 1 1
Lys146 (NZ) 1 1 1
Empty boxes indicate interactions that are common to at least two
complexes, whereas filled boxes represent unique MHC–peptide hy-
drogen bonds. The absence of a specific side chain is featured by a
cross.
was chosen to characterize strong H-bonds. Medium in-
teractions were assigned a frequency between 25 and 50%.
About 25 H-bonds have been identified for peptides 1
and 2 in complex with B*2703 and B*2705 while 50% less
could be found for the Gln2 analogue with the two sub-
types (Fig. 5). The distribution of strong and medium H-
bonds correlates well with the binding potency of the
peptide. A similar number of strong H-bonds were found
for complexes 1a, 1b, 2a and 2b, consistent with the simi-
lar binding efficiencies of peptides 1 and 2 to both sub-
types. On the other hand, a reduced number of medium
and/or strong H-bonds (peptide 3 in complex with the
two alleles) correlates with the decreased binding of this
peptide. The weakest binding potency (peptide 3 to
B*2703) could effectively be qualitatively and quantitat-
ively related to the distribution of intermolecular H-
bonds. Not only the number but also the quality of the
MHC–ligand interactions correlates well with the binding
potency.
To accurately localize the interactions that may explain
peptide specificity variations, all H-bonds with frequencies
higher than 50% were identified for the six complexes
(Table 3). The first noticeable difference between the two
HLA-B27 alleles is the H-bonding network between the
MHC residues involved in binding to the peptide P1
position. In HLA-B*2705, two amino acid side chains are
H-bonded to the peptide N-terminus (Tyr7/Tyr171 in the
crystal structure, Tyr7/Glu63 in the MD models) (Table 4,
Figs. 6–8). Both side chains are fixed by a subtle water-
relayed H-bond network involving proximal MHC side
chains (Tyr59, Glu45, Tyr171). Tyr59 is directly bound to
Tyr171, and indirectly to Tyr7, Glu45 and Glu63. The single
point mutation occurring for HLA-B*2703 (Tyr59→His)
perturbs this network. The bound water molecule disap-
pears and the peptide N-terminus binds to His59 and no
more to Tyr7 (Table 3, Fig. 7). The consequence on the
H-bond balance is a loss of one direct MHC–MHC inter-
action (His59 cannot interact with Tyr171) and five water-
mediated interactions for complex 3a (Fig. 7). The result-
ing conformational change may be well accommodated as
far as P2 is strongly bound to pocket B (His9, Thr24,
Glu45) and the resulting H-bonds are strong enough to
maintain the peptide in the binding groove (P2=Arg). If
P2 is not an arginine (peptide 3), the resulting interaction
to pocket B (Thr24 and Glu45 notably) is much weaker
and the conformational rearrangement at P1 is important
(see the three new H-bonds for the P1 position in com-
plex 3a, Fig. 7). The Arg to Gln change at the P2 posi-
tion of the bound peptide is better tolerated by HLA-
B*2705 (complex 3b, Fig. 8) as the Tyr59 side chain is still
able to fix the position of Tyr7. During the MD simula-
tion, the N-terminal Cα-N bond of the bound peptide has
rotated to gain a new H-bond to Glu63. However, it is
still bound to Tyr7 as in the reference structure. Import-
antly, the Gln2 side chain is bound to Glu45 and Tyr99,
thus providing additional interactions to pocket B when
compared to complex 3a (Fig. 8). The quality of the
interaction between Gln2 and pocket B is, however, much
inferior to that observed for peptide analogues 1 and 2
bearing an optimal Arg residue (Table 4), thus explaining
the reduced binding affinity of peptide 3 for HLA-
B*2705.
For the set of peptides studied here, the advantage of
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Arg over Ala at P1 could be quantified by the gain of
P1 P2 P3 P4 P5 P6 P7 P8 P9
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Fig. 9. Accessible versus buried surface areas of peptides 2 and 4 in complex with B*2703 (a) and B*2705 (b) alleles (see the legend to Fig. 4).
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Fig. 10. Intermolecular hydrogen bonds for peptides 2 and 4 in complex with B*2703 (a) and B*2705 (b) alleles (see the legend to Fig. 5).
two water accessible salt bridges to Glu63/Glu163 (Table 3).
However, this does not correspond to a higher binding
affinity of the Arg analogue when compared to the Ala1
peptide. An Ala side chain is much easier to desolvate
and optimally interacts with conserved apolar residues of
pocket A (Met5, Trp167), thus explaining a rather similar
binding affinity of peptides 1 and 2 to both subtypes.
However, the present model cannot fully explain recent
data, indicating that basic residues are overrepresented at
the P1 position of B*2703-bound natural ligands [23].
From a purely statistical point of view, various rotamers
of basic P1 side chains could develop a salt bridge with at
least three negatively charged amino acids located at the
rim of pocket A (Glu58, Glu63, Glu163), and thus stabilize
the MHC–peptide complex.
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MHC–peptide interaction energies
TABLE 4
MHC–PEPTIDE INTERACTION ENERGIES CALCULATED FROM THE LINEAR POISSON–BOLTZMANN EQUATION AND
AMBER FORCE-FIELD CALCULATIONS
Peptide ∆G0coul a ∆G0reac b ∆G0elec c ∆Helec d ∆Hvdw e ∆Gtot f ∆Htot g
1a −499 487 −12 −87 −90 −102 −177
1b −542 498 −44 −79 −97 −141 −176
2a −359 340 −19 −72 −77 0−96 −149
2b −389 335 −54 −75 −80 −134 −155
3a −306 334 −28 −44 −68 0−40 −112
3b −371 380 −09 −62 −67 0−58 −129
a ∆G0coul: Coulombic component of MHC–peptide electrostatic interaction energy (charge–charge, charge–dipole, dipole–dipole interactions). ∆G0coul
= ∆G0coul(P–L) − ∆G0coul(P) − ∆G0coul(L) [50], where P–L describes the protein–ligand complex, P the protein and L the ligand.
b ∆G0reac: corrected self-reaction field component of MHC–peptide electrostatic interaction energies (energy required to transfer a molecule from
a continuum dielectric (vacuum) to another (water). ∆G0reac = ∆G0reac(P–L) − ∆G0reac(P) − ∆G0reac(L). As the contribution of the protein–ligand complexes
(∆G0reac(P–L)) and of the isolated protein (∆G0reac(P)) could be omitted from the calculation without affecting the reliability of the results [61], this
component corresponds here to the free energy of peptide desolvation (−∆G0reac(L)).
c ∆G0elec: total electrostatic interaction energy (∆G0coul + ∆G0reac).
d ∆Helec: AMBER electrostatic interaction energy (ε = 4rij).
e ∆Hvdw: AMBER van der Waals interaction energy. ∆Hvdw = A/r12 − B/r6, where r is the distance between atom pairs and A and B are atom-type-
dependent parameters.
f ∆Gtot: total interaction energy (∆G0elec + ∆Hvdw).
g DHtot: total AMBER interaction enthalpy (∆Helec + ∆Hvdw).
TABLE 5
INFLUENCE OF A P1 β-AMINO ACID ON THE HLA-B27
SUBTYPE SELECTIVITY OF A MODIFIED HLA-B27
LIGAND
Peptide Sequence EC50 (µM)a
number B*2703 B*2705
(P1-RYQKSTEL)
2 P1=Ala 3.0 04.0
4 P1=Balb 7.5 20
a Concentration of the peptide (in µM) at which HLA-B27 fluor-
escence (measured by FMC analysis with an anti-B27 monoclonal
antibody) on RMA-S cells was half the maximum obtained with the
wild-type peptide (peptide 1, Table 1).
b Bal: β-alanine (H2N-CH2-CH2-CO).
Interaction energies were extrapolated for all six ener-
gy-minimized time-averaged conformations (Table 4) by
summing up the van der Waals nonbonded interaction
energy (calculated with the AMBER 4.0 force field) and
the electrostatic component (calculated by solving the
linear form of the Poisson–Boltzmann equation), as re-
cently described [60]. As both ligands and protein struc-
tures are very similar for all complexes, distortion ener-
gies as well as translational/rotational entropy losses upon
binding were neglected here. Moreover, the self-reaction
field energy component of the electrostatic interaction
energy was limited to the contribution of the isolated
peptide (free energy of desolvation) and calculated from
the bound-peptide coordinates extracted from the MHC–
peptide binary complexes. It has recently been shown that
neglecting the protein contribution to the self-reaction
field energy is indeed possible and does not alter the
reliability of the obtained results [61].
Our computational protocol is able to properly rank
the binding of the three peptides 1–3 to both MHC al-
leles. Peptide 3 clearly interacts much weaker than the
other two peptides 1 and 2, whatever the MHC allele.
The weakest interaction energy was observed for binding
of 3 to B*2703, and is thus in agreement with binding
data (Table 1). Force-field interaction enthalpies (calcu-
lated by summing up both AMBER van der Waals and
electrostatic components, using a dielectric permittivity of
4rij) were much less related to the observed binding data,
as peptide 2 was always disfavoured with regard to pep-
tide 1 (Table 4). Notably, taking into account the peptide
desolvation energy by the continuum eletrostatics method
permits to compensate for the weakest Coulombic interac-
tions provided by peptide 2 (P1=Ala) to both alleles, with
respect to that observed for the Arg1 analogue. It may be
noticed that the free electrostatic interaction energies
(∆G0elec, Table 4) computed by the continuum electrostatics
method were also in rather good qualitative agreement
with the binding data reported in Table 1. Hence, the
three peptides are highly polar and interact mainly via H-
bonds and salt bridges.
For an even more realistic ranking of highly polar li-
gands than those presented here, free energy perturbation
[62] is probably the method of choice. Unfortunately, the
enormous amount of CPU time that would be necessary
for this computation precludes its systematic use in fast
screening of a set of congeneric molecules. Synthesis and
in vitro binding assays in this case provided a faster and
experimentally determined answer.
MD simulation of MHC–peptide complexes could
relate observed binding potencies and allele specificity to
simple molecular criteria (inter-cmass distances, atomic
fluctuations, accessible surface areas, distribution and
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location of intermolecular H-bonds). A single point muta-
Bal1
Arg2
Tyr3
Gln4 Lys5
Ser6
Thr7
Glu8
Leu9
Tyr84
Asp77
Thr80
Leu81Leu95
Lys146
Trp147
Val152
Thr143Tyr123
Asp116
His114
Leu156Leu160
Tyr159
Glu163Trp167Tyr171
His59
Glu63
Glu45
Thr24
His9
Tyr99
Tyr7
Fig. 11. Energy-minimized time-averaged MD model of complex 4a. The MHC protein backbone is displayed as a solid cyan tube, with peptide-inter-
acting side chains. The bound peptide 4 is represented by sticks. The following color coding has been used: carbon, white (protein) or green (peptide);
nitrogen, blue; oxygen, red; sulfur, yellow. Bound water molecules are shown as cyan balls. Yellow broken lines indicate MHC–peptide H-bonds.
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Fig. 12. Energy-minimized time-averaged MD model of complex 4b (see the legend to Fig. 11).
tion in the HLA binding groove is sufficient to break an
H-bond network in the vicinity of the peptide N-terminus.
As previously suggested on the basis of peptide binding
analyses [28], this minor change strengthens even more
the binding role of the dominant anchor P2 side chain
(Arg) for one allele (HLA-B*2703) and explains why
changing P2 to Gln has more detrimental effects in pep-
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tide binding for HLA-B*2703 than for HLA-B*2705,
where compensatory stabilization of the MHC–peptide
complex is still possible by H-bonded MHC side chains.
Interestingly, the most spectacular consequence of pro-
tein/peptide variability affects an area far away (10 Å)
from the location of the point mutations. It concerns the
stability of the interaction between the peptidic C-ter-
minal residue and its complementary pocket F, which has
recently been shown to play a decisive role in linking
particular B27 alleles to spondyloarthropathies [24,26].
Protein-based design
Relating the structure of B27 subtypes to the sequence
of their naturally bound peptides is a crucial step in
identifying potential immunodominant epitopes that may
discriminate alleles and confer susceptibility or resistance
to autoimmune diseases. One striking feature concerns the
single point mutation (Tyr59His) distinguishing HLA-
B*2705 from HLA-B*2703, which is unique among HLA
proteins. It is believed that B*2703 selects a subset of the
peptides presented by HLA-B*2705 [34]. Recent studies
have identified some peptides that are naturally presented
by both subtypes, and at least one natural B*2705 ligand
(the undecamer RRYLENGKETL) is not presented by
B*2703 [23,63]. The only difference between both alleles
concerns the position 59 located in pocket A which inter-
acts with the N-terminal amino acid of the bound peptide
(Fig. 6). As pocket A is slightly wider for HLA-B*2703,
extending the peptide backbone towards His59 by replacing
the natural P1 residue by a β-amino acid should theoreti-
cally allow a better discrimination of both alleles. This
structural change should be much better accommodated by
HLA-B*2703 (H-bond between His59 and the N-terminus
of the P1 β-amino acid) than by HLA-B*2705, for which
a steric clash with the Tyr59 side chain may be expected.
Starting from the self-peptide 1 (RRYQKSTEL) nat-
urally presented by HLA-B*2705 [20] and B*2703 [23],
Ala and Bal (β-alanine) were substituted for the natural
Arg at P1 (Table 5). The Ala1 peptide analogue was here
taken as a reference for its strong binding to both sub-
types. The two ligands were synthesized and tested for
their binding to B*2703 and B*2705. As expected from
the topology of the binding cleft, only the Bal analogue
could discriminate between the two subtypes, with a bet-
ter binding to HLA-B*2703 (Table 5).
To rationalize the experimental binding data, the non-
natural ligand 4 was simulated a posteriori, in complex
with both alleles, using exactly the same conditions as
those employed for simulating the natural MHC–peptide
complexes (see the section Computational procedures).
Using two of the previously described molecular parame-
ters (accessible versus buried surface area of the bound
ligand, intermolecular H-bonds) as quality control of the
complex stability, peptide 4 was indeed found to be much
better accommodated by B*2703 than by B*2705 (Figs.
9 and 10). Interestingly, the weak binding of the β-Ala
peptide to B*2705 could also be related to a partial disso-
ciation of the C-terminus from its complementary pocket
F (Fig. 9), far away from the peptide mutation site. The
present data, in agreement with previous MD simulations
of different MHC–peptide complexes [9], suggest that the
expulsion of the C-terminus from pocket F could be the
very first event in the dissociation of weak binding pep-
tides from class I MHC binding grooves. The modified P1
position is, however, significantly more buried when the
host protein is the B*2703 allele (Fig. 9). A qualitative
and quantitative analysis of intermolecular hydrogen
bonds also supports the reported binding data. A total of
15 H-bonds could be depicted for complex 4b (peptide 4
in complex with B*2705), whereas 26 interactions have
been found for complex 4a (peptide 4 in complex with
B*2703, Fig. 10). However, this analysis was unable to
explain the reduced affinity of the β-Ala compound for
B*2703, when compared to that of the natural Ala ana-
logue 2 (Table 4). The slight differences seen in the epi-
tope stabilization assay are certainly too subtle for the
short MD runs reported here. They probably result from:
(i) the absence of a side chain at position P1 of ligand 4;
and (ii) a weaker binding contribution of the bulging
P4–P8 part, for which higher atomic fluctuations (data
not shown) and less nonbonded contacts (see the high
solvent accessibility of the P5 and P8 residues for ligand
4, Fig. 9) have been noticed. Energy-minimized time-
averaged conformations of both complexes (Figs. 11 and
12) clearly depict significant differences in the MHC
pocket A (Tyr59, Trp167, Tyr171), which deviates dramati-
cally from the starting crystal coordinates for B*2705
only (rmsd values from all pocket A atoms of 1.5 and 2.5
Å for B*2703 and B*2705, respectively). The major con-
formational alterations upon Bal1 binding were observed
for the Tyr59-Trp167-Tyr171 triad (rmsd values of 1.7 and
2.7 Å for B*2703 and B*2705, respectively)sl. As pre-
dicted, the Tyr59 side chain was shifted away from the
peptide N-terminus and is now interacting via a water
molecule with the β-alanine terminal ammonium (Fig.
12). In contrast, the β-amino acid can directly interact
with the larger pocket A of B*2703 through three H-
bonds to His59 (mutated position), Glu63 and Glu163 (Fig.
11). Another significant difference in the binding of pep-
tide 4 to both alleles concerns the C-terminal amino acid,
which has nearly lost, upon binding to B*2705, all H-
bonds to the polar side chains of pocket F (Tyr84, Thr143,
Lys146; compare Figs. 11 and 12). The incorporation of a
β-amino acid at P1 has modified the above described H-
bond network between MHC side chains and the peptide
N-terminus. The bound water molecule located in pocket
A of HLA-B*2705 (recall Fig. 6) has either disappeared
(B*2703, Fig. 11) or has been shifted towards the extreme
left end of the binding groove (B*2705, Fig. 12).
More importantly, these results show that the incor-
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poration of a β-amino acid in the peptide sequence does
not abrogate binding to HLA-B27 subtypes. Peptide 4 is
one of the very first ligands for which the backbone
modification of an anchor residue does not abolish class
I MHC binding. Up to now, only a retro-inverso (NH-
CO instead of CO-NH) and a reduced peptide bond
(CH2-NH instead of CO-NH) pseudopeptide analogue of
an HLA-A2-binding peptide have been proposed as suc-
cessful P1 modifications [64,65]. However, a β-amino acid
at P1 presents the advantage to preserve the backbone
direction of the peptide ligand and the H-bonding capac-
ity of the first peptide bond (to Glu63 and Tyr159), so that
less 3D conformational changes of the MHC binding cleft
are necessary to accommodate the modified ligand. The
recently described X-ray structure of an MHC–peptide–
TcR ternary complex [66] suggests that the latter feature
may be of particular importance for a proper recognition
of the MHC–ligand pair by a TcR. Furthermore, it opens
the door to the incorporation of β-amino acids at other
anchor positions, notably P2, P3 and P9. Potential TcR-
binding amino acids have already been replaced by vari-
ous organic spacers without affecting the binding of the
corresponding ligand to class I MHC proteins [38,67,68].
The present design study demonstrates that substituting
a β-amino acid for a natural residue is a further solution
for designing high-affinity MHC ligands with improved
stability and pharmacokinetic properties. This is an abso-
lute prerequisite for the therapeutic use of MHC ligands
either as MHC blockers [69] or as T-cell receptor antag-
onists [70].
Conclusions
MD simulations have been used in the present study as
a tool for explaining peculiar structure–activity relation-
ships at the level of the protein–ligand interaction com-
plexes. The current study is not aimed at quantitatively
ranking MHC ligands and predicting their binding affin-
ities. For that purpose, free energy calculations using
much longer equilibration and conformational sampling
would be necessary. More simply, dynamical properties of
the modeled complexes can be qualitatively well related
to known binding data. Notably, monitoring protein–
ligand intramolecular distances, the atomic mobility of
the bound ligands, the ratio of accessible versus buried
surface areas, the history and the quality of peptide–
protein H-bonds allow a clear discrimination of high-
affinity from weak-binding peptides. This computational
approach, based on the qualitative analysis of short MD
trajectories, has already been used to succesfully predict
the bound conformation of a natural HLA-A2-restricted
epitope [37] prior to X-ray structure determination [55],
to identify T-cell epitopes from the primary structure of
potentially interesting proteins [9] and to design high-
affinity nonnatural ligands [38,71]. Herewith, we propose
its application to the rationalization of peptide specificity
for closely related HLA alleles and the design of non-
natural ligands with increased specificity for one HLA-
B27 subtype. Identifying the molecular rules, fine tuning
peptide selection by HLA alleles is a crucial step for
better understanding the peptide–HLA interactions that
may confer either susceptibility or resistance to immuno-
logical diseases associated with particular HLA alleles.
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